Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
346 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Peritoneal Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2014', provides an overview of the Peritoneal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Peritoneal Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Peritoneal Cancer - Overview 10 Pipeline Products for Peritoneal Cancer - Comparative Analysis 11 Peritoneal Cancer - Therapeutics under Development by Companies 12 Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 17 Peritoneal Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Peritoneal Cancer - Products under Development by Companies 21 Peritoneal Cancer - Products under Investigation by Universities/Institutes 24 Peritoneal Cancer - Companies Involved in Therapeutics Development 25 Johnson & Johnson 25 Boehringer Ingelheim GmbH 26 F. Hoffmann-La Roche Ltd. 27 Amgen Inc. 28 AstraZeneca PLC 29 GlaxoSmithKline plc 30 Bioniche Life Sciences, Inc. 31 MedImmune, LLC 32 Daiichi Sankyo Company, Limited 33 Oxford BioMedica plc 34 Millennium Pharmaceuticals, Inc. 35 Novartis AG 36 Astellas Pharma Inc. 37 ImmunoGen, Inc. 38 Astex Pharmaceuticals, Inc. 39 Bayer AG 40 Incyte Corporation 41 Hemispherx Biopharma, Inc. 42 Celldex Therapeutics, Inc. 43 Active Biotech AB 44 Bionomics Limited 45 Oncolytics Biotech Inc. 46 OXiGENE, Inc. 47 Topotarget A/S 48 NeoStem, Inc. 49 Pharmacyclics, Inc. 50 Synta Pharmaceuticals Corp. 51 Oasmia Pharmaceutical AB 52 MabVax Therapeutics, Inc. 53 Acceleron Pharma, Inc. 54 TRION Pharma GmbH 55 Cerulean Pharma, Inc. 56 OncoMed Pharmaceuticals, Inc. 57 TetraLogic Pharmaceuticals 58 Merrimack Pharmaceuticals, Inc. 59 Innate Therapeutics Limited 60 CritiTech, Inc. 61 Immunotope, Inc. 62 Immunovaccine, Inc. 63 Pharma Mar, S.A. 64 VentiRx Pharmaceuticals, Inc. 65 Genelux Corporation 66 TRACON Pharmaceuticals, Inc. 67 Lee's Pharmaceutical Holdings Limited 68 Clovis Oncology, Inc. 69 EGEN, Inc. 70 Advanced Accelerator Applications 71 Sanofi Pasteur SA 72 Peritoneal Cancer - Therapeutics Assessment 73 Assessment by Monotherapy Products 73 Assessment by Combination Products 74 Assessment by Target 75 Assessment by Mechanism of Action 79 Assessment by Route of Administration 83 Assessment by Molecule Type 86 Drug Profiles 89 pazopanib hydrochloride - Drug Profile 89 trebananib - Drug Profile 93 paclitaxel - Drug Profile 96 binimetinib - Drug Profile 98 nintedanib - Drug Profile 102 bevacizumab - Drug Profile 105 trabectedin - Drug Profile 109 rucaparib phosphate - Drug Profile 112 sorafenib tosylate - Drug Profile 115 alisertib - Drug Profile 119 selumetinib sulfate - Drug Profile 123 SGI-110 - Drug Profile 126 abiraterone acetate - Drug Profile 129 tasquinimod - Drug Profile 132 dalantercept - Drug Profile 134 elesclomol - Drug Profile 136 belinostat - Drug Profile 138 TroVax - Drug Profile 141 SG-2000 - Drug Profile 144 pelareorep - Drug Profile 146 nintedanib - Drug Profile 150 catumaxomab - Drug Profile 153 CRLX-101 - Drug Profile 155 VTX-2337 - Drug Profile 157 gimatecan - Drug Profile 159 seribantumab - Drug Profile 161 exatecan mesylate - Drug Profile 164 TRC-105 - Drug Profile 166 EGEN-001 - Drug Profile 168 NSC-748933 - Drug Profile 170 INCB-24360 - Drug Profile 171 birinapant - Drug Profile 173 Cancer Stem Cell Therapy - Drug Profile 175 DPX-Survivac - Drug Profile 176 linsitinib - Drug Profile 179 CDX-1401 - Drug Profile 182 ganetespib - Drug Profile 184 demcizumab - Drug Profile 188 erismodegib - Drug Profile 191 GLONC-1 - Drug Profile 193 fosbretabulin tromethamine - Drug Profile 195 BNC-105P - Drug Profile 199 Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 201 birinapant + conatumumab - Drug Profile 203 abexinostat hydrochloride - Drug Profile 205 8H9-MAb - Drug Profile 207 IMT-1012 - Drug Profile 208 vCP-2292 - Drug Profile 209 paclitaxel - Drug Profile 210 OC-DC Vaccine - Drug Profile 212 MV-NIS Vaccine - Drug Profile 213 IMGN-853 - Drug Profile 215 Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 216 MesoCART - Drug Profile 217 rintatolimod - Drug Profile 218 Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 220 MIS-416 - Drug Profile 221 Theranean - Drug Profile 223 Peritoneal Cancer - Recent Pipeline Updates 224 Peritoneal Cancer - Dormant Projects 336 Peritoneal Cancer - Discontinued Products 337 Peritoneal Cancer - Product Development Milestones 338 Featured News & Press Releases 338 Appendix 341 Methodology 341 Coverage 341 Secondary Research 341 Primary Research 341 Expert Panel Validation 341 Contact Us 342 Disclaimer 342
List of Tables Number of Products under Development for Peritoneal Cancer, H2 2014 14 Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Development by Companies, H2 2014 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H2 2014 21 Comparative Analysis by Late Stage Development, H2 2014 22 Comparative Analysis by Clinical Stage Development, H2 2014 23 Comparative Analysis by Early Stage Development, H2 2014 24 Products under Development by Companies, H2 2014 25 Products under Development by Companies, H2 2014 (Contd..1) 26 Products under Development by Companies, H2 2014 (Contd..2) 27 Products under Investigation by Universities/Institutes, H2 2014 28 Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2014 29 Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 30 Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 31 Peritoneal Cancer - Pipeline by Amgen Inc., H2 2014 32 Peritoneal Cancer - Pipeline by AstraZeneca PLC, H2 2014 33 Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 34 Peritoneal Cancer - Pipeline by Bioniche Life Sciences, Inc., H2 2014 35 Peritoneal Cancer - Pipeline by MedImmune, LLC, H2 2014 36 Peritoneal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 37 Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H2 2014 38 Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 39 Peritoneal Cancer - Pipeline by Novartis AG, H2 2014 40 Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H2 2014 42 Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 43 Peritoneal Cancer - Pipeline by Bayer AG, H2 2014 44 Peritoneal Cancer - Pipeline by Incyte Corporation, H2 2014 45 Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2014 46 Peritoneal Cancer - Pipeline by Active Biotech AB, H2 2014 48 Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 50 Peritoneal Cancer - Pipeline by Topotarget A/S, H2 2014 52 Peritoneal Cancer - Pipeline by NeoStem, Inc., H2 2014 53 Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 54 Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 55 Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 56 Peritoneal Cancer - Pipeline by MabVax Therapeutics, Inc., H2 2014 57 Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 58 Peritoneal Cancer - Pipeline by TRION Pharma GmbH, H2 2014 59 Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 60 Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 62 Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 63 Peritoneal Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 64 Peritoneal Cancer - Pipeline by CritiTech, Inc., H2 2014 65 Peritoneal Cancer - Pipeline by Immunotope, Inc., H2 2014 66 Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H2 2014 68 Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 69 Peritoneal Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 71 Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 72 Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 73 Peritoneal Cancer - Pipeline by EGEN, Inc., H2 2014 74 Peritoneal Cancer - Pipeline by Advanced Accelerator Applications, H2 2014 75 Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2014 76 Assessment by Monotherapy Products, H2 2014 77 Assessment by Combination Products, H2 2014 78 Number of Products by Stage and Target, H2 2014 81 Number of Products by Stage and Mechanism of Action, H2 2014 85 Number of Products by Stage and Route of Administration, H2 2014 89 Number of Products by Stage and Molecule Type, H2 2014 92 Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 228 Peritoneal Cancer - Dormant Projects, H2 2014 340 Peritoneal Cancer - Discontinued Products, H2 2014 341
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
